Rise and shine, another busy day is on the way. Most days are busy, though, yes? So why not surrender to the rapid-fire pace and reach for a cup of stimulation to help the neurons get moving? Our coffee kettle stands ready, along with a pouch of glazed original doughnut, a flavor for the adventurous. As always, we have also assembled a few items of interest to move things along. We hope your day goes well and you conquer the world, such as it is. And please do reach out if you hear something saucy or have a secret dossier that needs a home. …
Germany, Italy, France, and Spain joined the ranks of European countries that temporarily halted use of the Covid-19 shot made by AstraZeneca (AZN) over blood-clot concerns, dealing another blow to the continent’s sluggish vaccination rollout and threatening the credibility of the vaccine itself, The Wall Street Journal says. The European Medicines Agency is expected by Thursday to give its verdict on safety and potential risks from a review of the reported cases. And STAT explains why this is a curious incident.
Moderna (MRNA) has begun studying its Covid-19 vaccine in children aged 6 months to 11 years in the U.S. and Canada, the latest effort to widen the mass-vaccination campaign beyond adults, The Wall Street Journal notes. The bulk of the U.S. Covid-19 vaccination campaign so far has focused on protecting adults, who are at higher risk of severe disease caused by the coronavirus than children. The first children have received doses in the study, which Moderna is conducting in collaboration with the National Institute of Allergy and Infectious Diseases.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect